Results 151 to 160 of about 15,332 (256)

Structural Restoration of an Unruptured Vertebral Artery Dissection Following Autologous Mesenchymal Stem Cell Therapy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Vertebral artery dissection (VAD) is a recognized cause of ischemic stroke, and current management relies on antithrombotic therapy that is not specifically directed at structural repair of the arterial wall. We report a man in his mid‐50s who presented with a sudden, severe right occipital headache after a golf swing and had a history of a ...
Hyungchang Kang   +3 more
wiley   +1 more source

Burnout and work-life balance: the generational points of view. [PDF]

open access: yesInsights Imaging
Molwitz I   +4 more
europepmc   +1 more source

Safety and Effectiveness of Denileukin Diftitox‐cxdl in Patients With Relapsed/Refractory Peripheral T‐Cell Lymphoma and Cutaneous T‐Cell Lymphoma: An All‐Case Post‐Marketing Study in Japan

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Introduction Denileukin diftitox (DD)‐cxdl, a fusion protein comprising diphtheria toxin fragments and human interleukin‐2, is a treatment for peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma (CTCL). Previous trials have enrolled a limited number of patients, and there is a need to evaluate DD‐cxdl in a more diverse population ...
Tatsuro Jo   +3 more
wiley   +1 more source

Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi‐Country Needs Assessment

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The treatment landscape for relapse/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) has evolved with recent novel agents. With the availability of novel agents that slow disease progression, managing treatment side effects and monitoring response in patients with these hematologic malignancies may ...
Patrice Lazure   +9 more
wiley   +1 more source

Current challenges and the way forwards for regulatory databases of artificial intelligence as a medical device. [PDF]

open access: yesNPJ Digit Med
Ong AY   +8 more
europepmc   +1 more source

Real‐World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2

open access: yesCancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Acute myeloid leukemia (AML) remains the most common cause of death in adults with acute leukemia. Tyrosine kinase inhibitors (TKIs) have shown significant clinical efficacy in defined patient subgroups. Real‐world outcomes of AML patients undergoing TKI therapy have not been widely reported.
Manuel R. Espinoza‐Gutarra   +4 more
wiley   +1 more source

The Role of Pharmacists in Tackling Mpox: Challenges and Future Prospects: A Narrative Review

open access: yesHealth Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Pharmacists play a key role in managing and mitigating mpox through clinical care, pharmacovigilance, vaccine management, and resilient supply chains. Management focuses on supportive care, infection prevention, and accurate diagnosis, with pharmacists ensuring the availability and rational use of vaccines, disinfectants ...
Ayalew Sirbemo Degebo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy